267 related articles for article (PubMed ID: 12845330)
1. Prophylactic fibrinolysis through selective dissolution of nascent clots by tPA-carrying erythrocytes.
Murciano JC; Medinilla S; Eslin D; Atochina E; Cines DB; Muzykantov VR
Nat Biotechnol; 2003 Aug; 21(8):891-6. PubMed ID: 12845330
[TBL] [Abstract][Full Text] [Related]
2. Thrombi--beware of red cells bearing gifts.
Ouriel K
Nat Biotechnol; 2003 Aug; 21(8):871-2. PubMed ID: 12894199
[No Abstract] [Full Text] [Related]
3. Fibrin affinity of erythrocyte-coupled tissue-type plasminogen activators endures hemodynamic forces and enhances fibrinolysis in vivo.
Ganguly K; Goel MS; Krasik T; Bdeir K; Diamond SL; Cines DB; Muzykantov VR; Murciano JC
J Pharmacol Exp Ther; 2006 Mar; 316(3):1130-6. PubMed ID: 16284278
[TBL] [Abstract][Full Text] [Related]
4. Novel and emerging therapies: thrombus-targeted fibrinolysis.
Lippi G; Mattiuzzi C; Favaloro EJ
Semin Thromb Hemost; 2013 Feb; 39(1):48-58. PubMed ID: 23034825
[TBL] [Abstract][Full Text] [Related]
5. The glycocalyx protects erythrocyte-bound tissue-type plasminogen activator from enzymatic inhibition.
Ganguly K; Murciano JC; Westrick R; Leferovich J; Cines DB; Muzykantov VR
J Pharmacol Exp Ther; 2007 Apr; 321(1):158-64. PubMed ID: 17215448
[TBL] [Abstract][Full Text] [Related]
6. Blood clearance and activity of erythrocyte-coupled fibrinolytics.
Ganguly K; Krasik T; Medinilla S; Bdeir K; Cines DB; Muzykantov VR; Murciano JC
J Pharmacol Exp Ther; 2005 Mar; 312(3):1106-13. PubMed ID: 15525799
[TBL] [Abstract][Full Text] [Related]
7. Human complement receptor type 1-directed loading of tissue plasminogen activator on circulating erythrocytes for prophylactic fibrinolysis.
Zaitsev S; Danielyan K; Murciano JC; Ganguly K; Krasik T; Taylor RP; Pincus S; Jones S; Cines DB; Muzykantov VR
Blood; 2006 Sep; 108(6):1895-902. PubMed ID: 16735601
[TBL] [Abstract][Full Text] [Related]
8. Cerebrovascular thromboprophylaxis in mice by erythrocyte-coupled tissue-type plasminogen activator.
Danielyan K; Ganguly K; Ding BS; Atochin D; Zaitsev S; Murciano JC; Huang PL; Kasner SE; Cines DB; Muzykantov VR
Circulation; 2008 Sep; 118(14):1442-9. PubMed ID: 18794394
[TBL] [Abstract][Full Text] [Related]
9. Function of tissue-type plasminogen activator releaser on vascular endothelial cells and thrombolysis in vivo.
Ueshima S; Matsuno H; Hayashi M; Horibuchi K; Okada K; Fukao H; Uematsu T; Matsuo O
Thromb Haemost; 2002 Jun; 87(6):1069-74. PubMed ID: 12083488
[TBL] [Abstract][Full Text] [Related]
10. Cerebral venous congestion as indication for thrombolytic treatment.
Tsai FY; Kostanian V; Rivera M; Lee KW; Chen CC; Nguyen TH
Cardiovasc Intervent Radiol; 2007; 30(4):675-87. PubMed ID: 17573553
[TBL] [Abstract][Full Text] [Related]
11. Sonothrombolysis for intraocular fibrin formation in an animal model.
Yamashita T; Ohtsuka H; Arimura N; Sonoda S; Kato C; Ushimaru K; Hara N; Tachibana K; Sakamoto T
Ultrasound Med Biol; 2009 Nov; 35(11):1845-53. PubMed ID: 19699025
[TBL] [Abstract][Full Text] [Related]
12. An experimental and theoretical study on the dissolution of mural fibrin clots by tissue-type plasminogen activator.
Wootton DM; Popel AS; Alevriadou BR
Biotechnol Bioeng; 2002 Feb; 77(4):405-19. PubMed ID: 11787013
[TBL] [Abstract][Full Text] [Related]
13. Multifunctional nanoagent for thrombus-targeted fibrinolytic therapy.
McCarthy JR; Sazonova IY; Erdem SS; Hara T; Thompson BD; Patel P; Botnaru I; Lin CP; Reed GL; Weissleder R; Jaffer FA
Nanomedicine (Lond); 2012 Jul; 7(7):1017-28. PubMed ID: 22348271
[TBL] [Abstract][Full Text] [Related]
14. Releasing the Brakes on the Fibrinolytic System in Pulmonary Emboli: Unique Effects of Plasminogen Activation and α2-Antiplasmin Inactivation.
Singh S; Houng A; Reed GL
Circulation; 2017 Mar; 135(11):1011-1020. PubMed ID: 28028005
[TBL] [Abstract][Full Text] [Related]
15. [Changes of blood coagulative and fibrinolytic system and function of pulmonary vascular endothelium after therapy in patients with acute pulmonary thromboembolism].
Pang BS; Wang C; Lu Y; Yang YH; Xing GH; Mao YL; Huang XX; Zhai ZG
Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(43):3074-8. PubMed ID: 18261355
[TBL] [Abstract][Full Text] [Related]
16. Highly stable plasminogen activator inhibitor type one (VLHL PAI-1) protects fibrin clots from tissue plasminogen activator-mediated fibrinolysis.
Jankun J; Aleem AM; Selman SH; Skrzypczak-Jankun E; Lysiak-Szydlowska W; Grafos N; Fryer HJ; Greenfield RS
Int J Mol Med; 2007 Nov; 20(5):683-7. PubMed ID: 17912461
[TBL] [Abstract][Full Text] [Related]
17. Tissue-type plasminogen activator-binding RNA aptamers inhibiting low-density lipoprotein receptor family-mediated internalisation.
Bjerregaard N; Bøtkjær KA; Helsen N; Andreasen PA; Dupont DM
Thromb Haemost; 2015 Jul; 114(1):139-49. PubMed ID: 25855589
[TBL] [Abstract][Full Text] [Related]
18. Effects of intra-abdominal administration of recombinant tissue plasminogen activator on coagulation, fibrinolysis and inflammatory responses in experimental polymicrobial peritonitis.
van Veen SQ; Meijers JC; Levi M; van Gulik TM; Boermeester MA
Shock; 2007 May; 27(5):534-41. PubMed ID: 17438459
[TBL] [Abstract][Full Text] [Related]
19. Plasmin induces local thrombolysis without causing hemorrhage: a comparison with tissue plasminogen activator in the rabbit.
Marder VJ; Landskroner K; Novokhatny V; Zimmerman TP; Kong M; Kanouse JJ; Jesmok G
Thromb Haemost; 2001 Sep; 86(3):739-45. PubMed ID: 11583303
[TBL] [Abstract][Full Text] [Related]
20. Locally applied recombinant plasmin results in effective thrombolysis in a porcine model of arteriovenous graft thrombosis.
Hoefer IE; Stroes ES; Pasterkamp G; Levi MM; Reekers JA; Verhagen HJ; Meijers JC; Humphries JE; Rotmans JI
J Vasc Interv Radiol; 2009 Jul; 20(7):951-8. PubMed ID: 19481472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
